 | Up a level |
Dibitetto, Diego; Liptay, Martin; Vivalda, Francesca; Dogan, Hülya; Gogola, Ewa; González Fernández, Martín; Duarte, Alexandra; Schmid, Jonas A; Decollogny, Morgane Francine; Francica, Paola; Przetocka, Sara; Durant, Stephen T; Forment, Josep V; Klebic, Ismar; Siffert, Myriam; de Bruijn, Roebi; Kousholt, Arne N; Marti, Nicole A; Dettwiler, Martina; Sørensen, Claus S; ... (2024). H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours. Nature communications, 15(4430) Nature Publishing Group 10.1038/s41467-024-48715-1
Akhoundova, Dilara; Francica, Paola; Rottenberg, Sven; Rubin, Mark A (2024). DNA Damage Response and Mismatch Repair Gene Defects in Advanced and Metastatic Prostate Cancer. Advances in anatomic pathology, 31(2), pp. 61-69. Lippincott Williams & Wilkins 10.1097/PAP.0000000000000422
Zelceski, Anabel; Francica, Paola; Lingg, Lea; Mutlu, Merve; Stok, Colin; Liptay, Martin; Alexander, John; Baxter, Joseph S; Brough, Rachel; Gulati, Aditi; Haider, Syed; Raghunandan, Maya; Song, Feifei; Sridhar, Sandhya; Forment, Josep V; O'Connor, Mark J; Davies, Barry R; van Vugt, Marcel A T M; Krastev, Dragomir B; Pettitt, Stephen J; ... (2023). MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells. Cell reports, 42(5), p. 112484. Cell Press 10.1016/j.celrep.2023.112484
Lingg, Lea; Rottenberg, Sven; Francica, Paola (2022). Meiotic genes and DNA double strand break repair in cancer. Frontiers in genetics, 13 Frontiers Media SA 10.3389/fgene.2022.831620
Bensimon, Ariel; Koch, Jonas P.; Francica, Paola; Roth, Selina M.; Riedo, Rahel; Glück, Astrid A.; Orlando, Eleonora; Blaukat, Andree; Aebersold, Daniel M.; Zimmer, Yitzhak; Aebersold, Ruedi; Medová, Michaela (2020). Deciphering MET-dependent modulation of global cellular responses to DNA damage by quantitative phosphoproteomics. Molecular oncology, 14(6), pp. 1185-1206. Elsevier 10.1002/1878-0261.12696
Francica, Paola; Rottenberg, Sven (2018). Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response. Genome medicine, 10(1), p. 101. BioMed Central 10.1186/s13073-018-0612-8
Nisa Hernández, Lluís; Häfliger, Pascal; Poliakova, Michaela; Giger, Roland; Francica, Paola; Aebersold, Daniel; Charles, Roch-Philippe; Zimmer, Yitzhak; Medova, Michaela (2017). PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models. Molecular cancer, 16(1), p. 93. BioMed Central 10.1186/s12943-017-0660-5
Francica, Paola; Aebersold, Daniel; Medova, Michaela (2017). Senescence as biologic endpoint following pharmacological targeting of receptor tyrosine kinases in cancer. Biochemical pharmacology, 126, pp. 1-12. Elsevier 10.1016/j.bcp.2016.08.022
Andreucci, Elena; Francica, Paola; Fearns, Antony; Martin, Lesley-Ann; Chiarugi, Paola; Isacke, Clare M; Morandi, Andrea (2016). Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts. OncoTarget, 7(49), pp. 80543-80553. Impact Journals LLC 10.18632/oncotarget.11826
Francica, Paola; Nisa Hernandez, Lluis; Aebersold, Daniel; Langer, Rupert; Bladt, Friedhelm; Blaukat, Andree; Keogh-Stroka, Deborah M.; Martínez, María Rodríguez; Zimmer, Yitzhak; Medova, Michaela (2016). Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer. Clinical cancer research, 22(21), pp. 5322-5336. American Association for Cancer Research 10.1158/1078-0432.CCR-15-2987
Mikami, K.; Medova, Michaela; Nisa Hernandez, Lluis; Francica, Paola; Glück, Astrid Andreina; Tschan, Mario; Blaukat, A.; Bladt, F.; Aebersold, Daniel; Zimmer, Yitzhak (2015). Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition-Associated Checkpoint Abrogation. Molecular cancer research, 13(12), pp. 1544-1553. American Association for Cancer Research AACR 10.1158/1541-7786.MCR-15-0022
Leiser, Dominic; Pochon, Benoît; Blank Wieslawa, Elzbieta; Francica, Paola; Glück, Astrid; Aebersold, Daniel; Zimmer, Yitzhak; Medova, Michaela (2014). Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation. FEBS letters, 588(5), pp. 653-658. Elsevier 10.1016/j.febslet.2013.12.025
Medová, Michaela; Pochon, Benoît; Streit, Bruno; Blank-Liss, Wieslawa; Francica, Paola; Stroka, Deborah; Keogh, Adrian; Aebersold, Daniel M.; Blaukat, Andree; Bladt, Friedhelm; Zimmer, Yitzhak (2013). The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants. Molecular cancer therapeutics, 12(11), pp. 2415-2424. American Association for Cancer Research AACR 10.1158/1535-7163.MCT-13-0151
